B

BPH Energy Ltd
ASX:BPH

Watchlist Manager
BPH Energy Ltd
ASX:BPH
Watchlist
Price: 0.011 AUD -15.38%
Market Cap: AU$13.4m

BPH Energy Ltd
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

BPH Energy Ltd
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
B
BPH Energy Ltd
ASX:BPH
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genetic Technologies Ltd
ASX:GTG
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Proteomics International Laboratories Ltd
ASX:PIQ
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Trajan Group Holdings Ltd
ASX:TRJ
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cryosite Ltd
ASX:CTE
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
E
EZZ Life Science Holdings Ltd
ASX:EZZ
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

BPH Energy Ltd
Glance View

BPH Energy Ltd. engages in the development of biomedical research and technologies within universities and hospital institutes. The company is headquartered in Perth, Western Australia. The company went IPO on 2004-08-06. The Company’s principal activities include Cortical Dynamics, Advent Energy Limited, Molecular Discovery Systems (MD Systems) and the HLS5 Project. Cortical Dynamics is working with BPH Energy and Swinburne University of Technology to develop and commercialize anaesthesia monitoring systems for use during surgery. Advent Energy Limited holds a portfolio of exploration assets throughout Australia and has its project in petroleum exploration permit 11. MD Systems is a class of anti-mitotic drugs, which has undergone preclinical testing of anti-cancer activity. MD Systems is working with the Western Australian Institute for Medical Research to develop and validate HLS5 as a tumor suppressor gene.

BPH Intrinsic Value
0.016 AUD
Undervaluation 33%
Intrinsic Value
Price
B

See Also

Back to Top